Diabetes mellitus and coronary revascularization procedures

International Journal of Cardiology

Volumn 119, Issue 1, 2007, Pages 10-14

  Anastasiadis, Kyriakos ^a   Moschos, Georgios ^b  

^a Kyanous Stavros Hospital   (Greece)

^b State Hospital   (Greece)

Author keywords

Angioplasty; Bypass graft; Coronary artery disease; Diabetic

Indexed keywords

ANGIOPLASTY; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; HEART MUSCLE REVASCULARIZATION; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RELEVANCE VECTOR MACHINE; REVIEW; TREATMENT OUTCOME;

CORONARY ARTERIOSCLEROSIS; DIABETES COMPLICATIONS; HUMANS; MYOCARDIAL REVASCULARIZATION;

EID: 34249306857     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.09.009     Document Type: Review

References (70)

1. Bonow R.O., and Gheorghiade M. The diabetes epidemic: a national and global crisis. Am J Med 116 (2004) S2-S10 [Suppl]
2. Creager M.A., Luscher T.F., Cosentino F., and Beckman J.A. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation 108 (2003) 1527-1532
3. Gaba M.K., Gaba S., and Clark L.T. Cardiovascular disease in patients with diabetes: clinical considerations. J Assoc Acad Minor Phys 10 (1999) 15-22
4. Hoogwerf B.J., Sheeler L.R., and Licata A.A. Endocrine management of the open heart surgical patient. Semin Thorac Cardiovasc Surg 3 (1991) 75-80
5. Brooks M.M., Jones R.H., and Bach R.G. Predictors of mortality and mortality from cardiac causes in the Bypass Angioplasty Revascularization Investigation (BARI) randomized trial and registry. Circulation 101 (2000) 2682-2689
6. Weisberg L.S., Kurnik P.B., and Kurnik B.R. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int 45 (1994) 259-265
7. Rensing B.J., Hermans W.R.M., Vos J., et al. Luminal narrowing after percutaneous transluminal coronary angioplasty: a study of clinical, procedural, and lesional factors related to long-term angiographic outcome. Circulation 88 (1993) 975-985
8. Przewlocki T., Pieniazek P., Ryniewicz W., et al. Long-term outcome of coronary balloon angioplasty in diabetic patients. Int J Cardiol 76 (2000) 7-16
9. Stein B., Weintraub W.S., Gebhart S.S.P., et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 91 (1995) 979-989
10. Kip K.E., Faxon D.P., Detre K.M., Yeh W., Kelsey S.F., and Currier J.W. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 94 (1996) 1818-1825
11. King III S.B., Kosinski A.S., Guyton R.A., Lembo N.J., and Weintraub W.S. Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST). J Am Coll Cardiol 35 (2000) 1116-1121
12. Van Belle E., Abolmaali K., Bauters C., et al. Restenosis, late vessel occlusion and left ventricular function six months after balloon angioplasty in diabetic patients. J Am Coll Cardiol 34 (1999) 476-485
13. Kereiakes D., Linnemeier T.J., Baim D.S., et al. Usefulness of stent length in predicting in-stent restenosis (the MULTI-LINK stent trials). Am J Cardiol 86 (2000) 336-341
14. Van Belle E., Perie M., Braune D., et al. Effects of coronary stenting on vessel patency and long-term clinical outcome after percutaneous coronary revascularization in diabetic patients. J Am Coll Cardiol 40 (2002) 410-417
15. Siegel R., Bhaskaran A., Barker B., et al. Stenting during coronary intervention improves procedural and long term clinical outcomes in diabetics. Eur Heart J 4 (2002) 306 [Suppl]
16. Van Belle E., Bauters C., Hubert E., et al. Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native coronary vessels. Circulation 96 (1997) 1454-1460
17. Stuckey T.D., Stone G.W., Cox D.A., et al. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). Am J Cardiol 95 (2005) 1-7
18. Naber C.K., Baumgart D., Bonan R., et al. Intracoronary brachytherapy, a promising treatment option for diabetic patients: Results from a European multicenter registry (RENO). Catheter Cardiovasc Interv 61 (2004) 173-178
19. Moses J.W., Moussa I., Leon M.B., et al. Effect of catheter-based iridium-192 gamma brachytherapy on the added risk of restenosis from diabetes mellitus after intervention for in-stent restenosis (subanalysis of the GAMMA I Randomized Trial). Am J Cardiol 90 (Aug 1 2002) 243-247
20. Sabate M., Pimentel G., Prieto C., et al. Intracoronary brachytherapy after stenting de novo lesions in diabetic patients: results of a randomized intravascular ultrasound study. J Am Coll Cardiol 44 (2004) 520-527
21. Marso S.P., Lincoff A.M., Ellis S.G., et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) diabetic substudy. Circulation 100 (1999) 2477-2484
22. Bhatt D.L., Marso S.P., Lincoff A.M., Wolski K.E., Ellis S.G., and Topol E.J. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 35 (2000) 922-928
23. Roffi M., Chew D.P., and Mukherjee D. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 104 (2001) 2767-2771
24. Roffi M., Moliterno D.J., Meier B., et al. Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up. Circulation 105 (2002) 2730-2736
25. Mehilli J., Kastrati A., Schuhlen H., et al. Intracoronary stenting and antithrombotic regimen: is abciximab a superior way to eliminate elevated thrombotic risk in diabetics (ISAR-SWEET) study investigators. Circulation 110 (2004) 3627-3635
26. Cohen Y., Raz I., Merin G., and Mozes B. Comparison of factors associated with 30-day mortality after coronary artery bypass grafting in patients with versus without diabetes melitus. Israely Coronary Artery Bypass (ISCAB) Study Consortium. Am J Cardiol 81 (1998) 7-11
27. Thourani V.H., Weintraub W.S., Stein B., et al. Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. Ann Thorac Surg 67 (1999) 1045-1052
28. Weintraub W.S., Stein B., Gebhart S.P., Craver J.M., Jones E.L., and Guyton R.A. The impact of diabetes on the initial and long term outcomes of coronary artery bypass surgery. Circulation 92 Suppl I (1995) I643
29. Herlitz J., Wognsen G.B., Emanuelsson H., et al. Mortality and morbidity in diabetic and nondiabetic patients during a 2-year period after coronary artery bypass grafting. Diabetes Care 19 (1996) 698-703
30. Hirotani T., Kameda T., Kumamoto T., Shirota S., and Yamano M. Effects of coronary artery bypass grafting using internal mammary arteries for diabetic patients. J Am Coll Cardiol 34 (1999) 532-538
31. Morricone L., Ranucci M., Denti S., et al. Diabetes and complications after cardiac surgery: comparison with a non-diabetic population. Acta Diabetol 36 (1999) 77-84
32. Whang W., and Bigger Jr. J.T. Diabetes and outcomes of coronary artery bypass graft surgery in patients with severe left ventricular dysfunction: results from The CABG Patch Trial database. J Am Coll Cardiol 36 (2000) 1166-1172
33. Risum O., Abdelnoor M., Svennevig J.L., et al. Diabetes mellitus and morbidity and mortality risks after coronary artery bypass surgery. Circulation 84 Suppl III (1991) III275-III284
34. French J.K., Scott D.S., and Whitlock R.M. Late outcome after coronary artery bypass graft surgery in patients < 40 years old. Circulation 92 Suppl II (1995) II14-II19
35. Herlitz J., Wognsen G.B., Karlson B.W., et al. Mortality, mode of death and risk indicators for death during 5 years after coronary artery bypass grafting among patients with and without a history of diabetes mellitus. Coron Artery Dis 11 (2000) 339-346
36. Trick W.E., Scheckler W.E., Tokars J.I., et al. Risk factors for radial artery harvest site infection following coronary artery bypass graft surgery. Clin Infect Dis 30 (2000) 270-275
37. O.'Keefe J.H., Blackstone E.H., Sergeant P., and McCalister B.D. The optimal mode of coronary revascularization for diabetics. A risk-adjusted long-term study comparing coronary angioplasty and coronary bypass surgery. Eur Heart J 19 (1998) 1696-1703
38. The BARI investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI). Circulation 96 (1997) 1761-1769
39. Morris J.J., Smith L.R., Jones R.H., et al. Influence of diabetes and mammary artery grafting on survival after coronary bypass. Circulation 84 Suppl III (1991) III275-III284
40. Weintraub W.S., Jones E.L., Craver J.M., Crosswald R., and Guyton R.A. In-hospital and long-term outcome after reoperative coronary artery bypass graft surgery. Circulation 92 Suppl II (1995) II50-II57
41. Magee M.J., Dewey T.M., Acuff T., et al. Influence of diabetes on mortality and morbidity: off-pump coronary artery bypass grafting versus coronary artery bypass grafting with cardiopulmonary bypass. Ann Thorac Surg 72 (2001) 776-780
42. Detre K.M., Guo P., Holubkov R., et al. Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 99 (1999) 633-640
43. Ferguson J.J. NHLBI BARI clinical alert on diabetics treated with angioplasty. Circulation 92 (1995) 3371
44. CABRI trial participants. First results of CABRI (Coronary Angioplasty versus Bypass Revascularization Investigation). Lancet 346 (1995) 1179-1184
45. Gum P.A., O'Keefe Jr. J.H., Borkon A.M., et al. Bypass surgery versus coronary angioplasty for revascularization of treated diabetic patients. Circulation 96 Suppl II (1997) II7-II10
46. Weintraub W.S., Stein B., Kosinski A., et al. Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease. J Am Coll Cardiol 31 (1998) 10-19
47. Serruys P.W., Unger F., Sousa E., et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 344 (2001) 1117-1124
48. Ischinger T.A. Outcome of diabetics in the Stent vs. CABG randomized trials: is stenting warranted?. Results presented at TCT (2002)
49. Sedlis S.P., Morrison D.A., Lorin J.D., et al. Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry. J Am Coll Cardiol 40 (2002) 1555-1566
50. Feit F., Brooks M.M., Sopko G., et al. Long-term clinical outcome in the Bypass Angioplasty Revascularization Investigation Registry. Comparison with the randomized trial. Circulation 101 (2000) 2795-2802
51. Vaz V.D., Ferreira E.J., Abizaid A., et al. Sustained suppression of neointimal hyperplasia by sirolimus eluting stents in diabetic patients: long-term angiographic and three-dimensional intravascular ultrasound follow-up. Am J Cardiol 94 Suppl 6A (2004) 74E
52. Moreira A., Sousa A., Abizaid A., et al. Does diabetes type influence late outcomes after sirolimus-eluting stent implantation using contemporary deployment technique?. Am J Cardiol 94 Suppl 6A (2004) 219E
53. Sabate M., Jimenez-Quevedo P., Angiolillo D.J., et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 112 (2005) 2175-2183
54. Moussa I., Leon M.B., Baim D.S., et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 109 (2004) 2273-2278
55. Hermiller J., Raizner A., and Cannon L. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol 45 (2005) 1172-1179
56. Guagliumi G., Urban P., Wijns W., et al. Real world experience in treating diabetic patients with sirolimus-eluting stent implantation: a 6-month follow-up report from the international e-CYPHER Registry. Am J Cardiol 94 Suppl 6A (2004) 73E
57. Ong A., Aoki J., and Rondriguez Granillo G. Comparison of short-(one month) and long-(twelve months) term outcomes of sirolimus-versus paclitaxel-eluting stents in 293 consecutive patients with diabetes mellitus (from the RESEARCH and T-SEARCH registries). Am J Cardiol 96 (2005) 358-362
58. Dibra A., Kastrati A., Mehilli J., et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 353 (2005) 663-670
59. Halushka P.V., Rogers R.C., Loadholt C.B., and Colwell J.A. Increased platelet thromboxane synthesis in diabetes mellitus. J Lab Clin Med 97 (1981) 87-96
60. De Silva S.R., Shawe J.E., Patel H., and Cudworth A.G. Plasma fibrinogen in diabetes mellitus. Diabetes Metab 5 (1979) 201-206
61. Tschoepe D., Roesen P., Kaufmann L., et al. Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur J Clin Invest 20 (1990) 166-170
62. Martina V., Bruno G.A., Trucco F., et al. Platelet cNOS activity is reduced in patients with IDDM and NIDDM. Thromb Haemost 79 (1998) 520-522
63. Moreno P.R., Murcia A.M., Palacios I.F., et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 102 (2000) 2180-2184
64. Goraya T.Y., Leibson C.L., Palumbo P.J., et al. Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. J Am Coll Cardiol 40 (2002) 946-953
65. Natali A., Vichi S., Landi P., Severi S., L'Abbate A., and Ferrannini E. Coronary atherosclerosis in Type II diabetes: angiographic findings and clinical outcome. Diabetologia 43 (2000) 632-641
66. Arad Y., Newstein D., Cadet F., et al. Association of multiple risk factors and insulin resistance with increased prevalence of asymptomatic coronary artery disease by an electron-beam computed tomographic study. Arterioscler Thromb Vasc Biol 21 (2001) 2051-2058
67. Yanagi K., Yamashita S., Kihara S., et al. Characteristics of coronary artery disease and lipoprotein abnormalities in patients with heterozygous familial hypercholesterolemia associated with diabetes mellitus or impaired glucose tolerance. Atherosclerosis 132 (1997) 43-51
68. Abaci A., Oguzhan A., Kahraman S., et al. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 99 (1999) 2239-22342
69. Corpus R.A., George P.B., House J.A., et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol 43 (2004) 8-14
70. McGuire D. Influence of the BARI/NHLBI diabetic clinical alert on practice patterns. Circulation 107 (2003) 1864-1870